We have located links that may give you full text access.
Lung Ultrasound Is Accurate for the Diagnosis of High-Altitude Pulmonary Edema: A Prospective Study.
Objective: The aim of this study was to assess the diagnostic accuracy of lung ultrasonography (LUS) for high-altitude pulmonary edema (HAPE).
Background: LUS has proven to be a reliable tool for the diagnosis of pulmonary diseases, including pneumonia, acute respiratory distress syndrome (ARDS), and pneumothorax. LUS also has potential for the diagnosis of HAPE. However, the actual diagnostic value of LUS for HAPE is still unknown. Our objective was to determine the feasibility of using LUS for the diagnosis of HAPE.
Materials and Methods: A prospective clinical research study of adult HAPE patients was conducted. LUS and chest X-ray (CXR) were performed in patients with suspected HAPE before and after treatment, and pulmonary moist rales were recorded concurrently. The diagnostic value of LUS, CXR, and moist rales for HAPE (i.e., their sensitivity, specificity, and positive and negative predictive values) were assessed, and the results were compared. The gold standard was the final diagnosis.
Results: In total, 148 patients were enrolled in the study, 126 of which were diagnosed with HAPE (85.14%). Before treatment, the diagnostic accuracy of LUS for HAPE was as follows: sensitivity, 98.41% (95% confidence interval (CI) 100.60-96.23%); specificity, 90.91% (95% CI 102.92-78.90%). LUS had higher sensitivity (0.98 vs. 0.81, P < 0.01 using the McNemar test) than moist rales for the diagnosis of HAPE. LUS also had higher sensitivity than CXR (0.98 vs. 0.93, P < 0.05 using the McNemar test). After treatment, LUS was consistent with CXR in 96.55% of HAPE patients, and the concordance between LUS and CXR was high ( k statistic = 0.483 P ≤ 0.001; 95% CI -0.021 to -0.853).
Conclusion: The results indicate that LUS is a reliable method for the diagnosis and surveillance of HAPE. This trial is registered with Chinese Clinical Trial Registry (No. ChiCTR-DDD-16009841).
Background: LUS has proven to be a reliable tool for the diagnosis of pulmonary diseases, including pneumonia, acute respiratory distress syndrome (ARDS), and pneumothorax. LUS also has potential for the diagnosis of HAPE. However, the actual diagnostic value of LUS for HAPE is still unknown. Our objective was to determine the feasibility of using LUS for the diagnosis of HAPE.
Materials and Methods: A prospective clinical research study of adult HAPE patients was conducted. LUS and chest X-ray (CXR) were performed in patients with suspected HAPE before and after treatment, and pulmonary moist rales were recorded concurrently. The diagnostic value of LUS, CXR, and moist rales for HAPE (i.e., their sensitivity, specificity, and positive and negative predictive values) were assessed, and the results were compared. The gold standard was the final diagnosis.
Results: In total, 148 patients were enrolled in the study, 126 of which were diagnosed with HAPE (85.14%). Before treatment, the diagnostic accuracy of LUS for HAPE was as follows: sensitivity, 98.41% (95% confidence interval (CI) 100.60-96.23%); specificity, 90.91% (95% CI 102.92-78.90%). LUS had higher sensitivity (0.98 vs. 0.81, P < 0.01 using the McNemar test) than moist rales for the diagnosis of HAPE. LUS also had higher sensitivity than CXR (0.98 vs. 0.93, P < 0.05 using the McNemar test). After treatment, LUS was consistent with CXR in 96.55% of HAPE patients, and the concordance between LUS and CXR was high ( k statistic = 0.483 P ≤ 0.001; 95% CI -0.021 to -0.853).
Conclusion: The results indicate that LUS is a reliable method for the diagnosis and surveillance of HAPE. This trial is registered with Chinese Clinical Trial Registry (No. ChiCTR-DDD-16009841).
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app